Quest Diagnostics Incorporated (DGX) Stock Analysis

Company Overview

Quest Diagnostics Incorporated operates within the healthcare sector, specifically focusing on the diagnostics and research industry where it delivers essential diagnostic testing and services across the United States. The company develops and provides a comprehensive suite of diagnostic information services that include routine and non-routine clinical testing, advanced clinical testing, anatomic pathology testing, and other specialized diagnostic information services. Its operational scale is significant, characterized by a market capitalization of $21.75 billion, annual revenue of $11.03 billion, and an employee base of 46,000 individuals. These valuation and revenue figures indicate that Quest Diagnostics holds a substantial position within the diagnostic market, reflecting its role as a major provider of laboratory services and data-driven health solutions.

Financial Health

The company reported a trailing twelve-month revenue of $11.03 billion with a net income of $988.00 million and an EBITDA of $2.18 billion. The substantial gap between the $11.03 billion in revenue and the $988.00 million in net income reveals a cost structure where operating expenses, including cost of goods sold and general administrative costs, consume approximately 91% of total revenue before reaching the bottom line. Quest Diagnostics generates $1.01 billion in free cash flow, which provides the organization with significant financial flexibility to fund operations, invest in technology, or manage capital expenditures without relying heavily on external financing. The company's profitability is further detailed by three key margins: a gross margin of 33.3%, an operating margin of 14.0%, and a profit margin of 9.0%. The gross margin of 33.3% indicates the efficiency of production and procurement, the operating margin of 14.0% reflects the effectiveness of overhead management, and the profit margin of 9.0% demonstrates the final profitability after all expenses and taxes. Regarding liquidity and leverage, Quest Diagnostics holds $420.00 million in cash against $6.58 billion in debt, resulting in a debt-to-equity ratio of 90.38, which suggests a leveraged balance sheet typical of capital-intensive service industries. Short-term liquidity is assessed via a current ratio of 1.04, indicating that current assets slightly exceed current liabilities, though the margin for error is relatively narrow. Management effectiveness is highlighted by a return on equity of 14.8% and a return on assets of 6.2%, metrics that show how efficiently the company generates profit from shareholder equity and its total asset base.

Valuation Assessment

Valuation metrics for Quest Diagnostics include a trailing P/E ratio of 22.32 and a forward P/E of 17.03. The difference between the trailing P/E of 22.32 and the forward P/E of 17.03 implies that the market expects earnings growth that will lower the multiple over the coming year, suggesting an anticipated improvement in profitability relative to current stock prices. The price-to-book ratio stands at 3.00, which indicates that the market values the company at three times its net asset value, reflecting a premium assigned to its intangible assets, brand, and future earnings potential rather than just its book equity. Alternative valuation measures include a price-to-sales ratio of 1.97 and an EV/EBITDA of 12.76, which suggest the company is valued slightly below the historical average for large-cap healthcare firms but commands a premium due to its stable cash flow generation. Price momentum is contextualized by a 52-week high of $213.50 and a 52-week low of $157.20, providing the range within which the stock has traded. While the current price is not explicitly listed in the provided facts, the beta value of 0.63 indicates that the stock exhibits lower volatility relative to the broader market, moving less aggressively than the overall index during periods of market fluctuation.

Growth & Income

The company's growth trajectory is defined by a revenue growth of 7.1% year-over-year and an earnings growth of 11.0% year-over-year. The earnings growth rate of 11.0% is expanding faster than the revenue growth rate of 7.1%, which implies that the company is benefiting from operational leverage and improved efficiency that allows net income to outpace top-line sales expansion. As a dividend payer, Quest Diagnostics offers a dividend yield of 1.8% with a payout ratio of 36.0%. This payout ratio is highly sustainable given the company's earnings, as retaining 64% of earnings allows for continued reinvestment in the business while returning capital to shareholders. The overall growth and income profile presents a scenario where the company delivers moderate revenue expansion, accelerating earnings growth through margin optimization, and supports a consistent, low-to-moderate dividend yield.